For a reproductive‑age woman with endometriosis‑related pain, is norethindrone or drospirenone (Slynd) the preferred progestin therapy?

Norethindrone vs Slynd (Drospirenone) for Endometriosis-Related Pain

Norethindrone is the preferred progestin for endometriosis-related pain because it is FDA-approved for this indication, has decades of clinical evidence demonstrating efficacy, and is recommended by ACOG guidelines, whereas Slynd (drospirenone) is only FDA-approved for contraception and has minimal evidence for endometriosis treatment. 1, 2, 3

FDA Approval Status and Guideline Support

• Norethindrone acetate is one of only two progestins FDA-approved specifically for treating endometriosis (the other being depot medroxyprogesterone acetate), establishing it as a proven therapeutic option 3

• Slynd (drospirenone 4 mg) is FDA-approved solely for contraception, not for endometriosis treatment 2

• ACOG guidelines explicitly list progestins including norethindrone as effective second-line options for endometriosis-related pain control 1

• The American Association of Clinical Endocrinologists recognizes norethindrone acetate (0.35 mg daily or 5 mg for 10-12 days/month) as an established progestational agent, though this guideline addresses menopause rather than endometriosis specifically 4

Clinical Efficacy Evidence for Norethindrone

• Norethindrone acetate achieves pain relief in 94.2% of patients with endometriosis-related dysmenorrhea, dyspareunia, and noncyclic pelvic pain 5

• In a 2025 randomized controlled trial comparing norethindrone acetate 5 mg daily versus dienogest, both achieved complete resolution of dysmenorrhea by 12 months (scores reduced from 7.43 to 0.00), but norethindrone demonstrated significantly greater reduction in endometrioma size (p=0.037) 6

• Long-term norethindrone acetate therapy (5 years) is safe and effective for rectovaginal endometriosis, with 68.8% of patients who completed treatment reporting satisfaction, and significant improvements in chronic pelvic pain and deep dyspareunia (p<0.001) 7

• Norethindrone acetate has a lower dropout rate (23.3%) compared to dienogest (47.5%) at 6 months (p=0.026), suggesting better tolerability 6

• When compared to extended-cycle oral contraceptives, norethindrone acetate 2.5 mg daily achieved 82.2% patient satisfaction at 12 months with significant amelioration of all pain symptoms 8

Limited Evidence for Drospirenone in Endometriosis

• Only one retrospective study (2024) evaluated drospirenone 4 mg for endometriosis in adolescents, showing that 67% reported less pain at follow-up, but 25% discontinued due to breakthrough bleeding 9

• This single study was retrospective, included only 61 patients, and lacked a control group—representing low-quality evidence compared to the multiple prospective trials and decades of data supporting norethindrone 9

• The study population was primarily adolescents (median age 18.9 years) with stage I disease, limiting generalizability to adult women with more severe endometriosis 9

Safety Considerations

Norethindrone Safety Profile

• Breakthrough bleeding is the most common side effect (57.6%), but only 7.7% of patients discontinue for this reason 5

• Long-term use (up to 5 years) demonstrates acceptable safety, with 38.1% withdrawing due to adverse effects over the entire treatment period 7

Slynd (Drospirenone) Safety Concerns

• Slynd is contraindicated in patients with renal impairment because drospirenone has antimineralocorticoid properties that can cause hyperkalemia 2

• Slynd is contraindicated in patients with hepatic impairment, as exposure increases three-fold in moderate liver disease 2

• Risk of hyperkalemia exists when combined with ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, NSAIDs, or aldosterone antagonists—medications commonly used in women with endometriosis for pain management 2

• Drospirenone requires 7 days of backup contraception if started >1 day after menses, compared to only 2 days for norethindrone 10

Practical Clinical Algorithm

For a woman with endometriosis-related pain:

1. First-line consideration: Norethindrone acetate 5 mg daily (or 2.5 mg daily as starting dose) 6, 5, 7

   • Proven efficacy for dysmenorrhea, dyspareunia, chronic pelvic pain, and dyschezia
   • FDA-approved indication
   • Decades of safety data

2. Screen for contraindications before prescribing either agent:

   • If renal impairment present: Norethindrone only (Slynd contraindicated) 2
   • If hepatic impairment present: Norethindrone only (Slynd contraindicated) 2
   • If taking potassium-sparing medications or NSAIDs: Norethindrone preferred (Slynd increases hyperkalemia risk) 2

3. Consider Slynd only if:

   • Patient has failed norethindrone due to intolerable side effects
   • Patient specifically requires the contraceptive properties of Slynd
   • Patient has no renal/hepatic impairment and is not taking interacting medications
   • Counsel that this is off-label use with limited evidence 9

Common Pitfalls to Avoid

• Do not assume all progestins are equivalent—each has distinct pharmacokinetic parameters, receptor affinities, and clinical evidence profiles 3

• Do not prescribe Slynd without checking renal function and medication list—the hyperkalemia risk is real and potentially dangerous 2

• Do not discontinue norethindrone prematurely for breakthrough bleeding—this is expected and usually improves with continued use; only 7.7% need to discontinue 5

• Do not use Slynd as first-line for endometriosis—it lacks FDA approval and robust evidence for this indication 2, 9

• Counsel patients that norethindrone can be used long-term (up to 5 years) safely if effective, unlike GnRH agonists which require time-limited use 7